Evaluating the Efficacy of Pulsating Electromagnetic Field Therapy by CRAD ULCER X-01 for Diabetic Foot Ulcers

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNational Defence University of Malaysia

About this trial

Background: Diabetic foot ulcer (DFU) is a frequent complication of chronic, uncontrolled diabetes mellitus (DM). Treatment with antibiotics, daily dressing, wound debridement, and wound off-loading is often prescribed. However, many DFU patients still progress into severe outcomes, including non-healing of wounds, infections, necrosis, and osteomyelitis. Prior research has shown that the application of pulsating electromagnetic field (PEMF) could accelerate wound healing, including in those afflicted with DFUs. Therefore, this study aimed to evaluate the efficacy of a locally developed CRAD ULCER X-01 device that uses the principles of PEMF in promoting DFU healing. Methods: A total of 32 patients with chronic, non-healing DFUs will be recruited from the Orthopaedic Clinic of Hospital Angkatan Tentera Tuanku Mizan and divided into control (C) (n=8) and treatment (T) (n=24) groups. All patients will receive a standard daily dressing. The PEMF will be supplemented for 1 hour/day, 2 hours/day, and 3 hours/day for T1, T2, and T3 subgroups, respectively (n=8 per group); whereas the C group will be controlled for placebo effect (device in-place but switched off). The therapy duration will be until the wound is closed or for a maximum period of three months. All patients will undergo wound assessment, wound edge tissue histology by haematoxylin and eosin (H\&E) staining, and immunohistology (for vascular endothelial growth factor \[VEGF\] and fibroblast growth factor 2 \[FGF-2\] expression), as well as serum superoxide dismutase (SOD) and C-reactive protein (CRP) at preand post-treatment, along with glycated haemoglobin (HbA1c) measurement only at post-treatment to control for confounder (i.e., glucose control for the past three months). This study hypothesizes that PEMF therapy by CRAD ULCER X-01 device will accelerate DFU healing and improve tissue integrity, with minimal systemic effects assessed via oxidative stress and inflammatory markers. Conclusion: The results from this study will validate PEMF's effectiveness in promoting DFU healing and establish the potential use of locally developed CRAD ULCER X-01 devices as supplementary therapy to standard DFU care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Provision of written consent by subjects.

Subject of either sex.

At least 18 years of age.

Known diabetes mellitus.

Disqualifiers

Inability or unwillingness to provide written consent.

Inability or unwillingness to comply with the requirements of the protocol as determined by the investigator.

Other medical conditions which, in the investigator's judgement, may be associated with increased risk to the subject or may interfere with study assessments or outcomes.

Participation in another clinical trial and/or recipient of investigational therapy within 4 weeks prior to screening visit.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Pulsating electromagnetic field

    Device

    The intervention in this study is PEMF therapy using CRAD ULCER X-01, which will be given to chronic DFU patients alongside wound dressing. The device projects high-voltage, high-frequency, and low-current electrical stimulation to the DFU wounds. The device operates in a stationary state at the lower end of the hospital bed of patients who are being treated. This is because it depends solely on the wall socket power source (100/220/240V-AC, 50/60 HZ input Supply). The position of the machine would be adjusted and locked using the adapted roller stand in the proximity of the patient's foot. The elevation of the device would then be adjusted through the adapted mechanical arm, allowing the air channel to face the patient's foot while having a gap of 10-15 cm in between the patient's wound and the air beam (non-contact).

Treatment groups

32 Participants
are divided into 4 treatment groups
Group A: ControlNo intervention 0 interventions
Group B: Treatment 1Experimental treatment 1 intervention
Group C: Treatment 2Experimental treatment 1 intervention
Group D: Treatment 3Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Rate of wound healing

Changes in wound size over the study duration

Time frame
3 months

Secondary outcomes

1

Tissue histology

Appearance of wound tissue under haematoxylin and eosin staining.

Time frame
3 months
2

Tissue immunohistology

Expression of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) in the wound tissue.

Time frame
3 months
3

Oxidative stress marker

Levels of superoxide dismutase or other oxidative stress biomarkers in the serum

Time frame
3 months
4

Inflammatory marker

Levels of C-reactive protein (CRP) or other inflammatory biomarkers in the serum

Time frame
3 months

Other outcomes

1

Glycated haemoglobin

Levels of HbA1c in the blood

Time frame
3 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.